NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $9.74 -0.26 (-2.60%) Closing price 04:00 PM EasternExtended Trading$9.70 -0.04 (-0.41%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cartesian Therapeutics Stock (NASDAQ:RNAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cartesian Therapeutics alerts:Sign Up Key Stats Today's Range$9.38▼$10.0250-Day Range$9.15▼$12.8552-Week Range$8.46▼$26.50Volume97,131 shsAverage Volume81,379 shsMarket Capitalization$253.24 millionP/E RatioN/ADividend YieldN/APrice Target$40.00Consensus RatingModerate Buy Company Overview Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions. At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations. By combining nucleoside‐modified mRNA with bespoke LNP carriers, the company seeks to enhance cellular uptake and reduce immunogenicity, positioning its pipeline candidates for both systemic and localized therapeutic interventions. Cartesian’s preclinical programs include immuno-modulatory candidates intended to boost anti-tumor immunity, as well as mRNA constructs designed to reestablish immune tolerance in autoimmune disease models. The firm has also entered strategic collaborations with academic institutions and contract research organizations to support IND-enabling studies and expand its translational research capabilities. Founded as a spin-out from leading academic research laboratories, Cartesian Therapeutics completed its initial public offering in 2021. Headquartered in New Jersey, the company engages with a broad network of scientific and clinical partners across North America and Europe. Cartesian’s leadership team includes experienced executives drawn from both biotech start-ups and larger pharmaceutical organizations, underscoring its commitment to advancing mRNA science from bench to bedside. As Cartesian progresses toward clinical milestones, it aims to establish itself as a key innovator in the rapidly evolving field of RNA therapeutics.AI Generated. May Contain Errors. Read More Cartesian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreRNAC MarketRank™: Cartesian Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 659th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCartesian Therapeutics has a consensus price target of $40.00, representing about 310.7% upside from its current price of $9.74.Amount of Analyst CoverageCartesian Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cartesian Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cartesian Therapeutics are expected to decrease in the coming year, from $4.56 to ($3.07) per share.Read more about Cartesian Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.64% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 35.4, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently decreased by 1.27%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted27.64% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 35.4, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently decreased by 1.27%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.78 News SentimentCartesian Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cartesian Therapeutics this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders60.30% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAC Stock News HeadlinesCartesian Therapeutics Announces New Employment Inducement GrantOctober 3, 2025 | globenewswire.comCartesian Therapeutics Insider Ups Holding During YearSeptember 18, 2025 | finance.yahoo.comGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.October 7 at 2:00 AM | Weiss Ratings (Ad)Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comCartesian Therapeutics to Participate in Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comMizuho Securities Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)August 15, 2025 | theglobeandmail.comBTIG Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)August 14, 2025 | theglobeandmail.comOppenheimer Sticks to Their Hold Rating for Cartesian Therapeutics (RNAC)August 14, 2025 | theglobeandmail.comSee More Headlines RNAC Stock Analysis - Frequently Asked Questions How have RNAC shares performed this year? Cartesian Therapeutics' stock was trading at $17.91 at the start of the year. Since then, RNAC shares have decreased by 45.6% and is now trading at $9.74. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) released its quarterly earnings data on Thursday, August, 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $1.26. The company earned $0.30 million during the quarter, compared to analyst estimates of $0.77 million. When did Cartesian Therapeutics' stock split? Cartesian Therapeutics's stock reverse split on the morning of Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cartesian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/07/2025Today10/07/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CIK1453687 Webselectabio.com Phone617-923-1400Fax617-924-3454Employees64Year Founded2016Price Target and Rating Average Price Target for Cartesian Therapeutics$40.00 High Price Target$42.00 Low Price Target$38.00 Potential Upside/Downside+311.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($52.83) Trailing P/E RatioN/A Forward P/E Ratio2.13 P/E GrowthN/ANet Income-$77.42 million Net MarginsN/A Pretax Margin-3,506.15% Return on EquityN/A Return on Assets-6.36% Debt Debt-to-Equity RatioN/A Current Ratio13.33 Quick Ratio13.33 Sales & Book Value Annual Sales$1.03 million Price / Sales246.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-36.02Miscellaneous Outstanding Shares26,002,000Free Float10,323,000Market Cap$252.87 million OptionableOptionable Beta0.39 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RNAC) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.